key: cord-0716203-7qz8fgtz
authors: Machovec, Kelly A.; Ames, Warwick A.
title: Evidence-Based Medicine in the Time of COVID: We Have a Problem
date: 2020-11-04
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2020.10.058
sha: 793144a82206fc156b45b1811d630b51a14c4747
doc_id: 716203
cord_uid: 7qz8fgtz

nan

Funding: None. Declaration of Interest: None.

A baby with D-transposition of the great arteries, intact ventricular septum and restrictive atrial septal communication was born to a COVID-19 positive mother. Urgent intervention was warranted, but balancing quality care with testing constraints and local logistical factors created a safety quagmire. Peri-natal transmission of COVID-19 virus is unlikely, and if occurs is likely due to close contact between infected mother and baby; vertical transmission is unlikely and has not yet been reported 1 . This baby had no contact with his mother after birth and the chance of positive test was not high; early repair would improve the baby's post-operative course and outcomes. At the same time, a complex congenital heart operation on a neonate with COVID-19 infection is potentially dangerous for the baby, as well as the staff who risk exposure.

This scenario has played out for many of us over the last months as we try to balance the risk of infection with the urgency of a given child's surgical condition. The severe acute respiratory syndrome due to coronavirus 2 infection (SARS-CoV-2) has highlighted innovation and resilience, but has also called attention to many deficiencies and inconsistencies in our health care system, both in the United States and worldwide. Our need for information about this new virus has outstripped our ability to conduct evidence-based research. Case series and even case reports are taking on elevated importance as we share data and make medical decisions.

Evidence based medicine (EBM) is purportedly our gold standard, but in reality, is not widely practiced. EBM is defined as the "use of best evidence with current expertise and patient values to guide health care decisions 2 . Systematic reviews and randomized, controlled trials form the apex of the EBM pyramid, but these types of studies are also subject to corruption. To be useful, randomized trials must ask the correct question, be designed to answer that question, and have adequate sample size, methodology, and follow up. To be useful in the situation of a particular patient, that patient must be similar to study patients.

Inappropriately applied evidence may cause harm. Given all of these caveats to the gold standard of applied research, it is not surprising that we have no proof that evidence-based medicine improves outcomes.

Large randomized trials are particularly lacking in pediatric populations, where target groups are smaller and research dollars harder to obtain. Attempting to apply EBM in pediatric congenital cardiac surgery and anesthesia further underscores the problems with holding EBM as the gold standard. Consider systematic reviews and metanalyses in the adult cardiac population -these often consider a homogenous population, with a higher ratio of randomized trial to observational or retrospective studies. In contrast, pediatric congenital cardiac patients are a heterogeneous population with high complexity, and it is difficult to prove outcomes benefits for a given strategy for a particular sub-population.

Database research has helped answer many clinical questions in congenital cardiac anesthesia and surgery. Database research is resource heavy, but not as resource heavy as randomized trials. The Society for Thoracic Surgeons Congenital Heart Database (STS CHDB) is a repository for peri-operative information on children and adults with congenital heart disease;

in 2010 the Congenital Cardiac Anesthesia Society began adding anesthetic data to the database. Currently, the STS CHDB collects information worldwide, capturing data on nearly all congenital heart surgery programs; anesthetic contribution is present in about 50% of programs 3 . Database research is hindered, however, by the quality of the data. The STS CHDB is only one of more than 40 registries addressing congenital heart disease; all of these registries must contend with issues of data integrity including missing values, risk adjustments, varied validation, oversight and data usage, and privacy concerns 4 . A secondary problem with using data obtained in registries is the time necessary to examine and report trends. We have many scenarios in medicine when clinical disease processes evolve at a pace faster than can be scientifically scrutinized and determined. Databases and registries processes move too slowly to inform bedside decisions for an individual patient who needs urgent surgery. EBM fails us in our current global pandemic, and in many cases of unique diseases.

Continuous quality improvement initiatives provide valuable opportunities to rapidly assess new interventions and strategies in patient care. Case reports and retrospective reviews should not be eschewed as "poor" evidence. We should encourage informal communication and facilitate real-time discussion of patient problems and creative solutions. Whilst we must be cautious over "fake news," we must remain open-minded as to the challenges of abrupt changes in clinical disease. Anecdotal and retrospective evidence is having a well-deserved moment in the spotlight. We should remember this when the pandemic is over and we are tempted to fall back into our old patterns of evidence judging.

Considerations for Pediatric Heart Programs During COVID-19: Recommendations From the Congenital Cardiac Anesthesia Society

How evidence-based medicine is failing due to biased trials and selective publication

The Congenital Cardiac Anesthesia Society-Society of Thoracic Surgeons Cardiac Anesthesia Database Collaboration

Clinical Databases and Registries in Congenital and Pediatric Cardiac Surgery, Cardiology, Critical Care, and Anesthesiology Worldwide

The Society of Thoracic Surgeons Congenital Heart Surgery Database: 2019 Update on Outcomes and Quality

Multisystem inflammatory syndrome in children and adolescents with COVID-19

Centers for Disease Control and Prevention. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019. (COVID-19). Available online at

Paediatric Multisystem Inflammatory Syndrome Temporally Associated With COVID-19

Pediatric Inflammatory Multisystem Syndrome: Statement by the Pediatric Section of the European Society for Emergency Medicine and European Academy of

Hyperinflammatory shock in children during COVID-19 pandemic

Multisystem Inflammatory Syndrome in Children in the United States. Reply